Growth hormone use in the treatment of idiopathic short stature

Current Opinion in Investigational Drugs

Volumn 9, Issue 4, 2008, Pages 396-401

  Zucchini, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Child; Growth hormone; Growth hormone therapy; Idiopathic short stature; Insulin growth factor 1; Puberty

Indexed keywords

GROWTH HORMONE RECEPTOR; GROWTH HORMONE SECRETAGOGUE; HUMAN GROWTH HORMONE; SOMATOMEDIN; STEROID;

BIRTH WEIGHT; BODY HEIGHT; BODY MASS; BONE DYSPLASIA; DRUG EFFICACY; DRUG USE; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GROWTH ACCELERATION; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HORMONE SENSITIVITY; HORMONE SUBSTITUTION; HUMAN; HYPOCHONDROPLASIA; PUBERTY; REVIEW; SHORT STATURE; TREATMENT RESPONSE; TURNER SYNDROME;

ADULT; BODY HEIGHT; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; PATIENT SELECTION; RECOMBINANT PROTEINS; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME;

EID: 41949087910     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Milner RD: Which children should have growth hormone therapy? Lancet (1986) 1(8479):483-485.
2. Martel LF, Biller HB (Eds): Stature and stigma: The biopsychosocial development of short males. Lexington Books, Lexington, MA, USA (1987).
3. Schumacher A: On the significance of stature in human society. J Hum Evol (1982) 11(8):697-701.
4. Cacciari E, Cicognani A, Pirazzoli P, Tassoni P, Salardi S, Capelli M, Zucchini S, Natali G, Righetti F, Ballardini D: Differences in somatomedin-C between short-normal subjects and those of normal height. J Pediatr (1985) 106(6):891-894.
5. Bright GM, Rogol AD, Johanson AJ, Blizzard RM: Short stature associated with normal growth hormone and decreased somatomedin-C concentrations: Response to exogenous growth hormone. Pediatrics (1983) 71(4):576-580.
6. Costin G, Kaufman FR: Growth hormone secretory patterns in children with short stature. J Pediatr (1987) 110(3):362-368.
7. Spiliotis BE, August GP, Hung W, Sonis W, Mendelson W, Bercu BB: Growth hormone neurosecretory dysfunction. A treatable cause of short stature. J Am Med Assoc (1984) 251(17):2223-2230.
8. Rudman D, Goldsmith M, Kutner M, Blackston D: Effect of growth hormone and oxandrolone singly and together on growth rate in girls with X chromosome abnormalities. J Pediatr (1980) 96(1):132-135.
9. Raiti S, Moore WV, Van Vliet G, Selna L: Growth-stimulating effects of human growth hormone therapy in patients with Turner syndrome. J Pediatr (1986) 109(6):944-949.
10. Kikuchi K, Fujisawa I, Momoi T, Yamanaka C, Kaji M, Nakano Y, Konishi J, Mikawa H, Sudo M: Hypothalamic-pituitary function in growth hormone-deficient patients with pituitary stalk transection. J Clin Endocrinol Metab (1988) 67(4):817-823.
11. Bressani N, di Natale B, Pellini C, Triulzi F, Scotti G, Chiumello G: Evidence of morphological and functional abnormalities in the hypothalamus of growth-hormone-deficient children: A combined magnetic resonance imaging and endocrine study. Horm Res (1990) 34(5-6):189-192.
12. Wit JM: Idiopathic short stature: Definition, spontaneous growth and response to treatment. In: Growth Hormone therapy in Pediatrics - 20 years of KIGS. Ranke MB, Price DA, Reiter EO (Eds) Karger, Basel (2007):309-318.
13. Wyatt DT, Mark D, Slyper A: Survey of growth hormone treatment practices by 251 pediatric endocrinologists. J Clin Endocrinol Metab (1995) 80(11):3292-3297.
14. Moore KC, Donaldson DL, Ideus PL, Gifford RA, Moore WV: Clinical diagnoses of children with extremely short stature and their response to growth hormone. J Pediatr (1993) 122(5 Pt 1):687-692. • Most short stature children in this study group had a positive response to hGH therapy regardless of the diagnosis.
15. Hardin DS, Woo J, Butsch R, Huett B: Current prescribing practices and opinions about growth hormone therapy: Results of a nationwide survey of paediatric endocrinologists. Clin Endocrinol (2007) 66(1):85-94. • This survey of US pediatric endocrinologists showed that poor growth velocity, poor target height and low IGF-1 levels, but not GH response to provocative stimuli, are the most used indicators to treat a child with GH.
16. Cacciari E, Tassoni P, Parisi G, Pirazzoli P, Zucchini S, Mandini M, Cicognani A, Balsamo A: Pitfalls in diagnosing impaired growth hormone (GH) secretion: Retesting after replacement therapy of 63 patients defined as GH deficient. J Clin Endocrinol Metab (1992) 74(6):1284-1289.
17. Ghigo E, Bellone J, Aimaretti G, Bellone S, Loche S, Cappa M, Bartolotta E, Dammacco F, Camanni F: Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children. J Clin Endocrinol Metab (1996) 81(9):3323-3327.
18. Loche S, Bizzarri C, Maghnie M, Faedda A, Tzialla C, Autelli M, Casini MR, Cappa M: Results of early reevaluation of growth hormone secretion in short children with apparent growth hormone deficiency. J Pediatr (2002) 140(4):445-449. • The findings of this study suggest that children with pathologic GH responses to provocative tests but normal magnetic resonance imaging findings should be reevaluated before performing a diagnosis of permanent GH deficiency, as most of them show a normal secretion after retesting.
19. Zucchini S, Pirazzoli P, Santoni R, Baronio F, Marsciani M, Gennari M, Balsamo M, Cicognani A: GH secretion during pharmacological and physiological tests is variously influenced by BMI, homa index and estrogen levels. 89th Annual Meeting of the Endocrine Society, Toronto (2007):Abs P2-514.
20. Melmed S, Kleinberg D: Anterior pituitary. In: Williams Textbook of Endocrinology. Kronenberg HM, Melmed S, Polansky KS, Larsen PR (Eds), Saunders Elsevier, Philadelphia, PA, USA (2007) 11:155-261.
21. Cohen P: Controversy in clinical endocrinology: Problems with reclassification of insulin-like growth factor I production and action disorders. J Clin Endocrinol Metab (2006) 91(11):4235-4236.
22. Maghnie M, Strigazzi C, Tinelli C, Autelli M, Cisternino M, Loche S, Severi F: Growth hormone (GH) deficiency (GHD) of childhood onset: Reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults. J Clin Endocrinol Metab (1999) 84(4):1324-1328.
23. Thomas M, Massa G, Maes M, Beckers D, Craen M, François I, Heinrichs C, Bourguignon JP, Belgian Study Group for Paediatric Endocrinology (BSGPE): Growth hormone (GH) secretion in patients with childhood-onset GH deficiency: Retesting after one year of therapy and at final height. Horm Res (2003) 59(1):7-15.
24. Zucchini S, Pirazzoli P, Baronio F, Gennari M, Bal MO, Balsamo A, Gualandi S, Cicognani A: Effect on adult height of pubertal growth hormone retesting and withdrawal of therapy in patients with previously diagnosed growth hormone deficiency. J Clin Endocrinol Metab (2006) 91(11):4271-4276. • This study demonstrated that GH therapy can be safely withdrawn in children with a previous diagnosis of GH deficiency if GH secretion normalizes at puberty.
25. Ranke MB, Lindberg A, Martin DD, Bakker B, Wilton P, Albertsson-Wikland K, Cowell CT, Price DA, Reiter EO: The mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency suggests a moderate role of GH dose. J Clin Endocrinol Metab (2003) 88(10):4748-4753. • This study suggests that total pubertal growth in idiopathic GH deficiency is only moderately dependent on GH dose and more dependent on auxological parameters.
26. Bryant J, Baxter L, Cave CB, Milne R: Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst Rev (2007) 18(3):CD004440. •• This paper represents the most recent and exhaustive review on the evidence of GH treatment in ISS: in the first case-controlled trial, girls treated with GH were 7.5 cm taller than untreated controls; in the second trial, children treated with GH were 3.7 cm taller than the placebo-treated group.
27. Buchlis JG, Irizarry L, Crotzer BC, Shine BJ, Allen L, MacGillivray MH: Comparison of final heights of growth hormone-treated vs untreated children with idiopathic growth failure. J Clin Endocrinol Metab (1998) 83(4):1075-1079.
28. Hintz RL, Attie KM, Baptista J, Roche A: Effect of growth hormone treatment on adult height of children with idiopathic short stature. Genentech Collaborative Group. N Engl J Med (1999) 340(7):502-507.
29. Wit JM, Rekers-Mombarg LT, Cutler GB, Crowe B, Beck TJ, Roberts K, Gill A, Chaussain JL, Frisch H, Yturriaga R, Attanasio AF: Growth hormone (GH) treatment to final height in children with idiopathic short stature: Evidence for a dose effect. J Pediatr (2005) 146(1):45-53.
30. Ranke MB, Lindberg A, Price DA, Darendeliler F, Albertsson-Wikland K, Wilton P, Reiter EO, KIGS International Board: Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. Horm Res (2007) 68(2):53-62. •• The findings of this study represent confirmation in a large case series that young children with ISS who show good first-year response to GH are likely to benefit from long-term treatment, even on low GH dosages.
31. Ranke MB, Lindberg A, Price DA, Darendeliler F, Albertsson-Wikland K, Wilton P, Reiter E: Short- and long-term response to GH in idiopathic short stature: KIGS analysis of factors predicting growth. In: Growth Hormone Therapy In Pediatrics - 20 Years of KIGS. Ranke MB, Price DA, Reiter EO (Eds), Karger, Basel, Switzerland (2007):319-325.
32. van der Werff ten Bosch JJ, Bot A: Growth of males with idiopathic hypopituitarism without growth hormone treatment. Clin Endocrinol (1990) 32:707-717.
33. Wit JM, Kamp GA, Rikken B: Spontaneous growth and response to growth hormone treatment in children with growth hormone deficiency and idiopathic short stature. Pediatr Res (1996) 39(2):295-302.
34. August GP, Julius JR, Blethen SL: Adult height in children with growth hormone deficiency who are treated with biosynthetic growth hormone: The National Cooperative Growth Study experience. Pediatrics (1998) 102(Pt 3):512-516.
35. Reiter EO, Price DA, Wilton P, Albertsson-Wikland K, Ranke MB: Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: Analysis of a large international database. J Clin Endocrinol Metab (2006) 91(6):2047-2054.
36. Cutfield WS, Karagiannis G, Reiter EO: GH treatment to final height in idiopathic GH deficiency: The KIGS experience. In: Growth hormone therapy in pediatrics-20 years of KIGS. Ranke MB, Price DA, Reiter EO (Eds), Karger, Basel (2007):145-162.
37. Cacciari E, Cicognani A, Pirazzoli P, Zucchini S, Salardi S, Balsamo A, Cassio A, Pasini A, Carlá G, Tassinari D, Gualandi S: Final height of patients treated for isolated GH deficiency: Examination of 83 patients. Eur J Endocrinol (1997) 137(1):53-60.
38. Zucchini S, Wasniewska M, Cisternino M, Salerno M, Iughetti L, Maghnie M, Street ME, Caruso-Nicoletti M, Cianfarani S: Adult height in children with short stature and idiopathic delayed puberty after different management. Eur J Pediatr (2007) [Epub ahead of print]. • In this study, subjects with short stature and idiopathic delayed puberty (particularly girls) do not reach a better adult height when treated with GH.
39. Achermann JC, Hamdani K, Hindmarsh PC, Brook CG: Birth weight influences the initial response to growth hormone treatment in growth hormone-insufficient children. Pediatrics (1998) 102(2 Pt 1):342-345.
40. Cacciari E, Zucchini S, Cicognani A, Pirazzoli P, Balsamo A, Salardi S, Cassio A, Pasini A, Gualandi S: Birth weight affects final height in patients treated for growth hormone deficiency. Clin Endocrinol (1999) 51(6):733-739.
41. Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K, Price DA: Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin Endocrinol Metab (1999) 84(4):1174-1183.
42. Blum WF, Crowe BJ, Quigley CA, Jung H, Cao D, Ross JL, Braun L, Rappold G, SHOX Study Group: Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: Two-year results of a randomized, controlled, multicenter trial. J Clin Endocrinol Metab (2007) 92(1):219-228.
43. Argente J, Gracia R, Ibáñez L, Oliver A, Borrajo E, Vela A, López-Siguero JP, Moreno ML, Rodríguez-Hierro F, Spanish SGA Working Group: Improvement in growth after two years of growth hormone therapy in very young children born small for gestational age and without spontaneous catch-up growth: Results of a multicenter, controlled, randomized, open clinical trial. J Clin Endocrinol Metab (2007) 92(8):3095-3101. • In this study, children aged two to five years, who were small for gestational age, showed a 2.1 SDS height gain after 2 years of GH treatment, with the children under four years of age having the greatest gain in growth velocity.
44. Davenport ML, Crowe BJ, Travers SH, Rubin K, Ross JL, Fechner PY, Gunther DF, Liu C, Geffner ME, Thrailkill K, Huseman C, Zagar AJ, Quigley CA: Growth hormone treatment of early growth failure in toddlers with Turner syndrome: A randomized, controlled, multicenter trial. J Clin Endocrinol Metab (2007) 92(9):3406-3416. • This study showed that after two years of GH treatment, 9-month to four-year old toddlers with Turner syndrome showed a 1.6 SDS height gain compared to untreated subjects.
45. Carel JC: Can we increase adolescent growth? Eur J Endocrinol (2004) 151(Suppl 3):U101-U108. • This review observed that current therapies used to increase pubertal growth (GH, LHRH analogue in particular) have so far obtained only modest or dubiously significant clinical results.
46. Kamp GA, Waelkens JJ, de Muinck Keizer-Schrama SM, Delemarre-Van de Waal HA, Verhoeven-Wind L, Zwinderman AH, Wit JM: High dose growth hormone treatment induces acceleration of skeletal maturation and an earlier onset of puberty in children with idiopathic short stature. Arch Dis Child (2002) 87(3):215-220.
47. Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG, American Norditropin Study Group: Insulin growth factor-based dosing of growth hormone therapy in children: A randomized, controlled study. J Clin Endocrinol Metab (2007) 92(7):2480-2486. •• This study provides robust evidence that titrating GH dose to achieve higher IGF-1 targets results in improved growth responses, although at higher average GH doses. Furthermore, there was up to 10 times variability of GH dose between subjects to maintain a similar IGF-1 level.
48. Perry JK, Emerald BS, Mertani HC, Lobie PE: The oncogenic potential of growth hormone. Growth Horm IGF Res (2006) 16(5-6):277-289.
49. Buzi F, Mella P, Pilotta A, Prandi E, Lanfranchi F, Carapella T: Growth hormone receptor polymorphisms. Endocr Dev (2007) 11:28-35.
50. Jorge AA, Marchisotti FG, Montenegro LR, Carvalho LR, Mendonca BB, Arnhold IJ: Growth hormone (GH) pharmacogenetics: Influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency. J Clin Endocrinol Metab (2006) 91(3):1076-1080.
51. Toyoshima MT, Castroneves LA, Costalonga EF, Mendonca BB, Arnhold IJ, Jorge AA: Exon 3-deleted genotype of growth hormone receptor (GHRd3) positively influences IGF-1 increase at generation test in children with idiopathic short stature. Clin Endocrinol (2007) 67(4):500- 504.
52. Clayton P, Tatò L, Chatelain P, Olivier C, Saunders H, Lamarine M, on behalf of the PREDICT Investigators Group: Gene expression profiling in prepubertal growth hormone (GH) deficient children with high versus low IGF-I responses after one month of GH therapy: The PREDICT study. 89th Annual Meeting of the Endocrine Society, Toronto (2007):Abs P1-264.